Ministerio_de_Economia_y_Competitividad
Ministerio_de_Economia_y_Competitividad

BIOSKETCH

ADOLFO LOPEZ DE MUNAIN  (UPDATED July 2020)


Adolfo Lopez de Munain Arregui was born on November 2, 1958 in Vitoria (Alava, Spain). He studied Medicine at the University of Navarra between 1975-1981 and received the PhD in 1992, with a doctoral thesis on myotonic dystrophy under direction of Prof. José Félix Martí Massó of the University of the Basque Country and Prof. José Manuel Martínez-Lage at the University of Navarra

Between 1983 and 1986 he completed his residency in Neurology at Hospital Ntra. Sra. de Aránzazu (San Sebastian, Guipúzcoa, Spain) under the direction of Prof. Martí Massó. During the residence he completed a training stay at the Neuromuscular Unit of the Hospital October 12, Madrid, Spain. After his formative period, began his career in the Neurology Department of the Hospital Ntra. Sra. de Aránzazu and later at the Hospital of Guipuzcoa. Between 2001-2017 was Head of Clinical Neurology at the Donostia Hospital in San Sebastian. Since September 2017 is the Head of de Department of Neurology of the Hospital Universitary Donostia. Between 2000 and 2007 he was also Senior Consultant at the Dementia Unit of the Matia Foundation (san Sebastián).

From his first years of professional activity, Dr. Lopez de Munain combined his clinical activity with the research activity. The common line of his work has been neurogenetic research with contributions in several clinical fields of Neurology. In addition to the main line in neuromuscular diseases, he actively participated in the design and implementation of other lines of clinical and molecular research in neurodegenerative diseases (frontotemporal dementias, prion diseases, ALS and Parkinson's disease among others) in multiple sclerosis and organized REIG (Spanish Network Multidisciplinary Research Group of Glioblastoma). He is author or coauthor of more than 280 peer-reviewed articles, 26 book chapters and more than 400 communications to national and international conferences and invited lectures. In this period he has been Director or co-director of 18 doctoral theses on some of the exposed lines.

He is an active member of the Spanish Society of Neurology, where he served as coordinator of the study groups on Neuromuscular Diseases and Neurogenetics. He also served as President of the Society of Neurology of the Basque Country (2012-2016). He is also an active member of the Spanish Association of Human Genetics, the World Muscle Society and Eusko Ikaskuntza (Basque Studies Society). He is also the founder of the NEUROGENES that integrates professionals from different disciplines interested in the development of Neurogenetics, REDELA, ALGESCO and DEGESCO (similar research networks in ALS and dementing disorders). He is a member of the Editorial Board of Neurologia, Revista de Neurología and the Spanish edition of Neurology, the Expert Committees of the Spanish Multiple Sclerosis Association and Spanish Association of Patients with Neuromuscular Diseases (ASEM), Myasthenia Association and Fundación LUZON. Dr. López de Munain is the current PI of the Donostia group at the Center for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED) driven by the Carlos III Health Institute and member of its Steering Committee and Director of Donostia Node of Basque Biobank of Tissues and DNA for Research. He is also a member of the Board of the Matia Foundation and the Council of the Division of Health and Quality of Life of TECNALIA. In addition to his career as a neurologist and biomedical researcher, Dr. Lopez de Munain is a BsC in Historical Sciences and Associate Professor of Neurology at the University of the Basque Country and co-founder of MIRAMOON Pharma, an start-up specialized in drug discovery and MIAKER DEVELOPMENTS SL a company devote to scientific services to make possible the translation of scientific knowledge to the companies.

Solicitamos su permiso para obtener datos estadísticos de su navegación en esta web, en cumplimiento del Real Decreto-ley 13/2012. Si continúa navegando consideramos que acepta el uso de cookies. OK | Más información